TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25022828

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (Clop-75)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg (Pras-5)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg (Pras-10)
Number of subjects: 72
Study: 25022839

Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 35

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 35
Study: 25022935

Group type: EXPERIMENTAL
Intervention: Omentin-1 levels in AMI patients at baseline: 18.73 ± 3.66 ng/ml
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) levels in AMI patients at baseline
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Interleukin-18 (IL-18) levels in AMI patients at baseline
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: White blood cells count (WBC) in AMI patients at baseline
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Chemerin levels in AMI patients at baseline: 263.37 ± 73.32 ng/ml
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ejection fraction in AMI patients at baseline
Number of subjects: 78

Group type: COMPARATOR
Intervention: Comparison of AMI patients with healthy controls
Number of subjects: 78
Study: 25023004

Group type: EXPERIMENTAL
Intervention: Acute ischaemic atherothrombotic stroke (IAS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acute coronary syndromes (ACS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carotid distensibility
Number of subjects: 100
Study: 25023199

Group type: EXPERIMENTAL
Intervention: Intention-to-treat principles reinforced by vigilant senior investigators during trial conduct
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lack of understanding of intention-to-treat principles by trial personnel
Number of subjects: 0
Study: 25023626

Group type: EXPERIMENTAL
Intervention: RT-qPCR (multimarker assay)
Number of subjects: 271

Group type: COMPARATOR
Intervention: ICC (immunocytochemistry)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: RT-qPCR (KRT19 marker)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: RT-qPCR (TWIST1 marker)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: RT-qPCR (hMAM marker)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Concordance between RT-qPCR and ICC
Number of subjects: 271
Study: 25023888

Group type: EXPERIMENTAL
Intervention: Liraglutide (50 μg/kg; i.p.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (10 mg/kg; i.p.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide (50 μg/kg; i.p., daily for 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine (0.5 mg/kg; p.o. for 8-9 weeks)
Number of subjects: 0
Study: 25023926

Group type: EXPERIMENTAL
Intervention: Modified Portfolio Diet (MPD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Time controls (no diet therapy)
Number of subjects: 30
Study: 25024076

Group type: EXPERIMENTAL
Intervention: RVD induction (lenalidomide, bortezomib, dexamethasone) followed by transplantation and RVD consolidation
Number of subjects: 31
Study: 25024303

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R (infusional dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine, prednisone, and rituximab)
Number of subjects: 24
Study: 25025522

Group type: EXPERIMENTAL
Intervention: Social marketing program
Number of subjects: 7101

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7101
Study: 25025611

Group type: EXPERIMENTAL
Intervention: Existing prognostic models for the Glasgow Outcome Scale Extended (GOS-E) at 6 months after injury (based on CRASH study data and Nijmegen data)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Multivariable analyses of predictors for lower 3- and 6-month GOS-E
Number of subjects: 386
Study: 25025963

Group type: EXPERIMENTAL
Intervention: Olaparib (up to 400 mg bid) plus liposomal doxorubicin (PLD) 40 mg m(-2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Olaparib (up to 400 mg bid) plus PLD 40 mg m(-2)
Number of subjects: 44
Study: 25027734

Group type: EXPERIMENTAL
Intervention: Non-obese girls
Number of subjects: 73

Group type: COMPARATOR
Intervention: Obese girls
Number of subjects: 73
Study: 25027873

Group type: EXPERIMENTAL
Intervention: HFrEF with anemia (group 1)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: HFrEF without anemia (group 2)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Chronic kidney disease control group (group 3)
Number of subjects: 151
Study: 25028353

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (serum 25OHD < 50 nmol/L)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sufficient Vitamin D (serum 25OHD ≥ 50 nmol/L)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 62
Study: 25028485

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 1961
Study: 25029231

Group type: EXPERIMENTAL
Intervention: Malnutrition assessment using the Patient-Generated Subjective Global Assessment (PG-SGA) questionnaire
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: cGVHD of the lungs, gastrointestinal (GI) tract, and mouth, NIH global score, cGVHD symptoms, worse functioning, low albumin, poorer survival, and low BMI
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Predictive model based on cGVHD of the lungs, GI tract, mouth, and BMI
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PG-SGA questionnaire
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Nutritional support interventions
Number of subjects: 210
Study: 25029335

Group type: EXPERIMENTAL
Intervention: cGAMP stimulation of peripheral-blood mononuclear cells and fibroblasts from patients and controls
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: JAK inhibitors on lymphocytes from affected children
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HEK293T cells transfected with mutant STING constructs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: cGAMP exposure of endothelial cells
Number of subjects: 6
Study: 25030780

Group type: EXPERIMENTAL
Intervention: Red meat consumption >100 g/d
Number of subjects: 74645

Group type: EXPERIMENTAL
Intervention: Processed red meat consumption (100 g/d)
Number of subjects: 74645

Group type: EXPERIMENTAL
Intervention: Nonprocessed red meat consumption (high and moderate intakes)
Number of subjects: 74645

Group type: COMPARATOR
Intervention: No red meat consumption
Number of subjects: 74645
Study: 25030840

Group type: EXPERIMENTAL
Intervention: Oral QLT091001 (10-40 mg/m(2) per day for 7 days)
Number of subjects: 14
Study: 25032816

Group type: EXPERIMENTAL
Intervention: Prednisone treatment for 12 weeks
Number of subjects: 0
Study: 25032995

Group type: EXPERIMENTAL
Intervention: diVIsive Shuffling Approach (VIStA)
Number of subjects: 140
Study: 25034386

Group type: EXPERIMENTAL
Intervention: COPD patients (SAF measurement)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Healthy controls (SAF measurement)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: COPD patients across GOLD stages (SAF measurement)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: COPD patients (association with lung function)
Number of subjects: 202
Study: 25034977

Group type: EXPERIMENTAL
Intervention: plm60-s at 10 mg/m(2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: plm60-s at 18 mg/m(2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: c-MI at 10 mg/m(2)
Number of subjects: 20
Study: 25036269

Group type: EXPERIMENTAL
Intervention: ICDs with or without CRT-D
Number of subjects: 0
Study: 25036504

Group type: EXPERIMENTAL
Intervention: OSAHS patients during sleep
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal controls during sleep
Number of subjects: 21
Study: 25036713

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n = 3; 6.4 nmol/kg, n = 24; 12.8 nmol/kg, n = 24)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54
Number of subjects: 53
Study: 25037041

Group type: EXPERIMENTAL
Intervention: Maternal vitamin D insufficiency (<32 ng/mL)
Number of subjects: 352

Group type: COMPARATOR
Intervention: ART-treated pregnant women
Number of subjects: 352
Study: 25037144

Group type: EXPERIMENTAL
Intervention: Bupropion plus aripiprazole
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: SSRI/SNRI plus aripiprazole
Number of subjects: 292
Study: 25037310

Group type: EXPERIMENTAL
Intervention: Parachute device implantation
Number of subjects: 39
Study: 25037684

Group type: EXPERIMENTAL
Intervention: IV trebananib 15 mg/kg QW plus paclitaxel 175 mg/m(2) Q3W and carboplatin 6 mg/mL · min Q3W followed by trebananib 15 mg/kg QW monotherapy for 18 months
Number of subjects: 27
Study: 25037759

Group type: EXPERIMENTAL
Intervention: Diagnosis-informed counseling
Number of subjects: 151
Study: 25037863

Group type: EXPERIMENTAL
Intervention: Continuous daily oral afatinib (30 mg starting dose, escalation to 50 mg) combined with intravenous pemetrexed (500 mg/m2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pulsed-dose daily oral afatinib (50 mg starting dose, escalation to 70 mg) combined with intravenous pemetrexed (500 mg/m2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both dosing schedules (SA and SB)
Number of subjects: 53
Study: 25038014

Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound (US)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Computed tomography (CT) scan
Number of subjects: 28
Study: 25038354

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin for 12 weeks
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin for 24 weeks
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin treatment
Number of subjects: 223
Study: 25038774

Group type: EXPERIMENTAL
Intervention: Ischaemic presentations in the 90 days before AMI
Number of subjects: 16439

Group type: COMPARATOR
Intervention: No prior ischaemic presentations
Number of subjects: 16439
Study: 25038824

Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2, 2 h) + Irinotecan (125 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2, 2 h) + Irinotecan (165 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2, 2 h) + Irinotecan (95 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Number of subjects: 20
Study: 25039025

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) measurement
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for hypertension
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for low high-density lipoprotein cholesterol
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for divorced marital status
Number of subjects: 840
Study: 25039696

Group type: EXPERIMENTAL
Intervention: Girls with ASD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Boys with ASD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Typically developing peers (control group)
Number of subjects: 100
Study: 25040144

Group type: EXPERIMENTAL
Intervention: Serum 1,3-beta-d-glucan (BDG) testing prior to initiation of antifungal (AF) treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Serum 1,3-beta-d-glucan (BDG) testing in patients who had undergone surgical procedures
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clinical decision based on BDG results
Number of subjects: 66
Study: 25040462

Group type: EXPERIMENTAL
Intervention: venlafaxine 150 mg/day for 6 weeks
Number of subjects: 140
Study: 25041850

Group type: EXPERIMENTAL
Intervention: da Vinci SP Surgical System (single-port robotic surgery)
Number of subjects: 19
Study: 25041904

Group type: EXPERIMENTAL
Intervention: LI-RADS categorization of nodules recognized at CT or MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LI-RADS Management Working Group consensus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LI-RADS guidelines
Number of subjects: 0
Study: 25042202

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg per day plus R-CHOP
Number of subjects: 33
Study: 25042419

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 2655

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2655

Group type: EXPERIMENTAL
Intervention: Killip class III or IV
Number of subjects: 2655

Group type: EXPERIMENTAL
Intervention: Impaired left ventricular ejection fraction
Number of subjects: 2655

Group type: EXPERIMENTAL
Intervention: Final TIMI flow 0-2
Number of subjects: 2655

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 2655

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2655

Group type: EXPERIMENTAL
Intervention: Peak CK
Number of subjects: 2655
Study: 25042797

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) at 120, 180, and 240 μg with ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) at 240 μg with ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) at all doses with ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a/ribavirin
Number of subjects: 0
Study: 25043069

Group type: EXPERIMENTAL
Intervention: 300 mg loading dose (LD)
Number of subjects: 840

Group type: COMPARATOR
Intervention: 75 mg maintenance dose (MD)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: 300 mg loading dose (LD) in CYP2C19 loss-of-function carriers
Number of subjects: 840

Group type: COMPARATOR
Intervention: 75 mg maintenance dose (MD) in CYP2C19 loss-of-function carriers
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: 300 mg loading dose (LD) in CYP2C19 non-carriers
Number of subjects: 840

Group type: COMPARATOR
Intervention: 75 mg maintenance dose (MD) in CYP2C19 non-carriers
Number of subjects: 840
Study: 25043320

Group type: EXPERIMENTAL
Intervention: Citalopram (response at 4th week)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Citalopram (remission at 12th week)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Citalopram (response)
Number of subjects: 470
Study: 25043483

Group type: EXPERIMENTAL
Intervention: Postmortem magnetic resonance (PMMR) imaging
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional autopsy
Number of subjects: 400
Study: 25043597

Group type: EXPERIMENTAL
Intervention: Bodybuilding HDS
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Nonbodybuilding HDS
Number of subjects: 839

Group type: COMPARATOR
Intervention: Medications
Number of subjects: 839
Study: 25043869

Group type: EXPERIMENTAL
Intervention: suPAR levels in patient groups (initial level 18.8 ng/mL, range 6.8-30.1 ng/mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: suPAR levels in control group (initial level 6.0 ng/mL, range 3.7-10.8 ng/mL)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CRP levels in patient groups
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for suPAR
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for CRP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cut-off value for suPAR
Number of subjects: 66
Study: 25045404

Group type: EXPERIMENTAL
Intervention: Dance Program (DP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Self-Selected Physical Activity Program (SSP)
Number of subjects: 100
Study: 25045579

Group type: EXPERIMENTAL
Intervention: ICG-PDR
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: SAPS II
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: pro-ADM
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: copeptin
Number of subjects: 110
Study: 25046246

Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy and psychotherapy (cognitive behavioral therapy or psychoeducation)
Number of subjects: 160
Study: 25047021

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 4789
Study: 25047061

Group type: EXPERIMENTAL
Intervention: Screening tests including PSA, free to total PSA, MRI of prostate, and prostate biopsy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creation of a bio-bank of tissue, urine, and serum from the cohort.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of an inception cohort for future interventional studies.
Number of subjects: 0
Study: 25047123

Group type: EXPERIMENTAL
Intervention: Lenvatinib (E7080) administered twice daily in 3-week cycles; 2 weeks of treatment followed by 1 week of rest.
Number of subjects: 27
Study: 25047658

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory II
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Correlation between Pittsburgh Sleep Quality Index and Beck Depression Inventory II
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Days with mild/moderate pain
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: History of headaches
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Age, body mass index, days of pain, severe acute painful events
Number of subjects: 328
Study: 25047720

Group type: EXPERIMENTAL
Intervention: ModuLAAr Ambient Assisted Living system
Number of subjects: 0
Study: 25047747

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy plus bevacizumab
Number of subjects: 2203
Study: 25047979

Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5mg daily) with prednisone (for the first 3 cycles)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pomalidomide with prednisone
Number of subjects: 29
Study: 25047992

Group type: EXPERIMENTAL
Intervention: Diabetes non-acceptance (measured by the Acceptance and Action Diabetes Questionnaire)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Diabetes self-care/glycaemic control
Number of subjects: 320
Study: 25048824

Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 2886

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 2886
Study: 25049247

Group type: EXPERIMENTAL
Intervention: 200 mg posaconazole once daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 300 mg posaconazole once daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Posaconazole tablets
Number of subjects: 54
Study: 25049249

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artemisinin (ART)-based combination therapies (ACTs)
Number of subjects: 0
Study: 25050705

Group type: EXPERIMENTAL
Intervention: Sodium gluconate (NaG)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both sodium gluconate (NaG) and monosodium glutamate (MSG)
Number of subjects: 154
Study: 25052051

Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate 60 mg intravenous over 24 hours every 2 weeks
Number of subjects: 24
Study: 25052451

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² on days 1 and 8 and cisplatin 70 mg/m² on day 1 every 21 days with lenalidomide 10 mg daily on days 1-14 (phase Ib).
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin (GCL) regimen without lenalidomide (control group not explicitly mentioned but implied as standard treatment).
Number of subjects: 9
Study: 25052720

Group type: EXPERIMENTAL
Intervention: IMRT-HT (Intensity Modulated Radiation Therapy delivered by helical tomotherapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cardiac myoview tests
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6-month follow-up chest CT-scans
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 30
Study: 25053535

Group type: EXPERIMENTAL
Intervention: INCRAFT AAA Stent Graft System
Number of subjects: 60
Study: 25053761

Group type: EXPERIMENTAL
Intervention: GATEp (prototype version of GATE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: GATEe (clinical trial version implemented in EyeSuite)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GATEp
Number of subjects: 30

Group type: COMPARATOR
Intervention: GATEe
Number of subjects: 30
Study: 25053760

Group type: EXPERIMENTAL
Intervention: Spaeth/Richman Contrast Sensitivity Test (SPARCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelli-Robson chart
Number of subjects: 0
Study: 25054539

Group type: EXPERIMENTAL
Intervention: Right middle lobe (RML) contribution to emphysema (% low attenuation area, LAAinsp<-950 HU at end-inspiration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right middle lobe (RML) contribution to gas trapping (%LAAexp<-856 HU at end-expiration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of RML with spirometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole lung CT metrics correlation with spirometry excluding RML
Number of subjects: 0
Study: 25056132

Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients (2006 vs 2009)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 0
Study: 25056438

Group type: EXPERIMENTAL
Intervention: Cold exposure (CE) in BAT(+) group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cold exposure (CE) in BAT(-) group
Number of subjects: 12
Study: 25056500

Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 0
Study: 25056691

Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAAs) ingestion (13 g; 2.4 g of Leu)
Number of subjects: 13
Study: 25057165

Group type: EXPERIMENTAL
Intervention: HPV-positive locoregionally advanced (LA) disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deintensified treatment regimens for HPV-positive LA OPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV-targeted strategies (vaccines)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV-positive recurrent/metastatic (RM) disease
Number of subjects: 0
Study: 25057177

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg i.v. weekly added to rituximab (375 mg/m2 i.v. day 1) and cladribine (5 mg/m2/day i.v. days 1-5 of a 28-day cycle)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg i.v. weekly added to rituximab and cladribine
Number of subjects: 17
Study: 25057265

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 274

Group type: COMPARATOR
Intervention: Nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs)
Number of subjects: 274